Adamas Pharmaceuticals, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was USD 19.311 million compared to USD 14.481 million a year ago. Operating loss was USD 9.525 million compared to USD 13.108 million a year ago. Net loss was USD 12.573 million compared to USD 16.648 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.59 a year ago.